Search results :

Fludarabine

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: L01BB05

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7
Body temperature increased 11% - 69% x x x x x x x
Vomiting 31% - 36% x x x x x x x
Infection 12% - 44% x x x x x x x
Nausea 1% - 36% x x x x x x x
Asthenia 9% - 65% x x x x x x x
Fatigue 10% - 38% x x x x x x x
Pain 5% - 22% x x x x x x x
Pneumonia 3% - 22% x x x x x x x
Cough 0% - 44% x x x x x x x
Rash 4% - 15% x x x x x x x
Chills 11% - 19% x x x x x x x
Oedema 8% - 19% x x x x x x x
Anorexia 0% - 34% x x x x x x x
Diarrhoea 5% - 15% x x x x x x x
Upper respiratory tract infection 2% - 16% x x x x x x x
Myalgia 4% - 16% x x x x x x
Abdominal pain 8% - 10% x
Dyspnoea 1% - 22% x x x x x x x
Visual disturbance 3% - 15% x x x x x x x
Gastrointestinal haemorrhage 3% - 13% x x x x x x x
Paraesthesia 4% - 12% x x x x x x
Herpes simplex 7% - 8% x
Rhinitis 3% - 11% x
Malaise 6% - 8% x x x x x x x
Back pain 4% - 9% x
Influenza 5% - 8% x
Pharyngitis 0% - 9% x x x x x x
Stomatitis 0% - 9% x x x x x x x
Urinary tract infection 2% - 15% x x x x x x x
Sweating increased 0% - 14% x x x x x x x
Hearing impaired 2% - 6% x x x x x x
Dysuria 3% - 4% x x x x x x
Oedema peripheral 0% - 7% x
Haemoptysis 1% - 6% x x x x x x
Hyperglycaemia 1% - 6% x x x x x x
Weight decreased 1% - 6% x
Sinusitis 0% - 5% x x x x x x x
Alveolitis allergic 0% - 6% x x x x x x
Angina pectoris 0% - 6% x x x x x x
Headache 0% - 9% x x x x x x x
Skin disorder 0% - 6% x
Lactic dehydrogenase activity increased 0% - 6% x
Cough increased 0% - 6% x
Chest pain 0% - 5% x
Haematuria 2% - 3% x x x x x x x
Constipation 1% - 3% x x x x x x
Phlebitis 1% - 3% x x x x x x
Pruritus 1% - 3% x x x x x x
Deep vein thrombosis 1% - 3% x x x x x x
Liver function test abnormal 1% - 3% x x x x x x
Sleep disorder 1% - 3% x x x x x x
Alopecia 0% - 3% x x x x x x
Arrhythmia 0% - 3% x x x x x x
Cholelithiasis 0% - 3% x x x x x x
Oesophagitis 0% - 3% x x x x x x
Cardiac failure congestive 0% - 3% x x x x x x
Myocardial infarction 0% - 3% x x x x x x
Cerebrovascular accident 0% - 3% x x x x x x
Supraventricular tachycardia 0% - 3% x x x x x x
Urinary hesitation 0% - 3% x x x x x x
Bronchitis 0% - 9% x x x x x x x
Osteoporosis 0% - 2% x x x x x x
Mucosal inflammation 0% - 2% x x x x x x
Anaphylactic shock 0% - 1% x x x x x x
Aneurysm 0% - 1% x x x x x x
Arthralgia 0% - 1% x x x x x x
Cerebellar syndrome 0% - 1% x x x x x x
Transient ischaemic attack 0% - 1% x x x x x x
Dysphagia 0% - 1% x x x x x x
Dehydration 0% - 1% x x x x x x
Epistaxis 0% - 1% x x x x x x
Haemorrhage 0% - 1% x x x x x
Proteinuria 0% - 1% x x x x x x
Renal failure 0% - 1% x x x x x x x
Seborrhoeic dermatitis 0% - 1% x x x x x x
Tumour lysis syndrome 0% - 1% x x x x x x x
Hepatic failure 0% - 1% x x x x x x
Renal function test abnormal 0% - 1% x x x x x x
Hypoxia 0% - 1% x x x x x x
Cytopenia postmarketing x x x x x x x
Progressive multifocal leukoencephalopathy postmarketing x x x x x x
Pancytopenia postmarketing x x x x x x x
Pulmonary fibrosis postmarketing x x x x x x x
Acute respiratory distress syndrome postmarketing x
Pulmonary haemorrhage postmarketing x x x x x x x
Bone marrow depression postmarketing x x x x x x x
Fatal outcomes postmarketing x x x x x x
Aplasia postmarketing x x x x x x x
Respiratory distress postmarketing x x x x x x x
Pulmonary toxicity postmarketing x x x x x x x
Respiratory failure postmarketing x x x x x x x
Anaemia x x x x x x x
Haemolytic anaemia x x x x x
Autoimmune haemolytic anaemia x x x
Skin cancer x x x x
Coma x x x x x x x
Confusional state x x x x x x x
Toxic epidermal necrolysis x x x x
Erythema multiforme x x x x
Fibrosis x x x x x x x
Flank pain x x x x x x x
Cardiac failure x x x
Herpes zoster x x x x
Hyperkalaemia x x x x x x x
Hypersensitivity x x x x x x x
Hypocalcaemia x x x x x x x
Acute myeloid leukaemia x x x x
Lymphoproliferative disorder x x x x
Myelodysplastic syndrome x x x x
Neoplasm x x x
Neutropenia x x x x x x x
Opportunistic infection x x x x x x x
Optic nerve disorder x x x x
Optic neuritis x x x x
Pemphigus x x x x
Pericardial effusion x x x x x x x
Neuropathy peripheral x x x x x x x
Convulsion x x x x
Stevens-Johnson syndrome x x x x
Thrombocytopenia x x x x x x x
Viral infection x x x x
Agitation x x x x x x x
Hyperphosphataemia x x x x x x x
Cystitis haemorrhagic x x x x x x x
Urate crystalluria x x x x x x x
Haemoglobin decreased x x x x x x x
Metabolic acidosis x x x x x x x
Wrist drop x x x x x x x
Digestion impaired x x x x x x x
Neurotoxicity x
Lung infiltration x x x x x x x
Autoimmune thrombocytopenia x x x x
Hepatobiliary disease x x x
Evans syndrome x x x x
Platelet count decreased x x x x x x x
Blindness x x x x
Hyperuricaemia x x x x x x x
Myelosuppression x x x x x x x
Thrombocytopenic purpura x x x x
Lung infection x
Acquired haemophilia x x x x
Skin toxicity x x x x x x x
Absolute neutrophil count decreased x x x x x x x
Cerebral haemorrhage x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

FLUDARABINE

Side effects:82
Source:FDA Structured Product Label

FLUDARABINE

Side effects:104
Source:FDA Structured Product Label

Fludarabine

Side effects:107
Source:FDA Structured Product Label

fludarabine

Side effects:125
Source:FDA Structured Product Label

FLUDARABINE

Side effects:129
Source:FDA Structured Product Label

FLUDARABINE

Side effects:129
Source:FDA Structured Product Label

FLUDARABINE

Side effects:129
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label